University of Kentucky

UKnowledge
Theses and Dissertations--Psychology

Psychology

2016

OVARIAN HORMONES, ADHD, RISK-TAKING, & IMPULSIVITY
Bethan A. Roberts
University of Kentucky, bethan.roberts@uky.edu
Digital Object Identifier: https://doi.org/10.13023/ETD.2016.423

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Recommended Citation
Roberts, Bethan A., "OVARIAN HORMONES, ADHD, RISK-TAKING, & IMPULSIVITY" (2016). Theses and
Dissertations--Psychology. 104.
https://uknowledge.uky.edu/psychology_etds/104

This Doctoral Dissertation is brought to you for free and open access by the Psychology at UKnowledge. It has
been accepted for inclusion in Theses and Dissertations--Psychology by an authorized administrator of
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

STUDENT AGREEMENT:
I represent that my thesis or dissertation and abstract are my original work. Proper attribution
has been given to all outside sources. I understand that I am solely responsible for obtaining
any needed copyright permissions. I have obtained needed written permission statement(s)
from the owner(s) of each third-party copyrighted matter to be included in my work, allowing
electronic distribution (if such use is not permitted by the fair use doctrine) which will be
submitted to UKnowledge as Additional File.
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and
royalty-free license to archive and make accessible my work in whole or in part in all forms of
media, now or hereafter known. I agree that the document mentioned above may be made
available immediately for worldwide access unless an embargo applies.
I retain all other ownership rights to the copyright of my work. I also retain the right to use in
future works (such as articles or books) all or part of my work. I understand that I am free to
register the copyright to my work.
REVIEW, APPROVAL AND ACCEPTANCE
The document mentioned above has been reviewed and accepted by the student’s advisor, on
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of
the program; we verify that this is the final, approved version of the student’s thesis including all
changes required by the advisory committee. The undersigned agree to abide by the statements
above.
Bethan A. Roberts, Student
Dr. Michelle Martel, Major Professor
Dr. Mark Fillmore, Director of Graduate Studies

OVARIAN HORMONES, ADHD, RISK-TAKING, & IMPULSIVITY
________________________________________________________
DISSERTATION
________________________________________________________
A dissertation submitted in partial fulfillment
of the requirements for the degree of Doctor of Philosophy
in the College of Arts and Sciences at the University of Kentucky
By
Bethan Anne Roberts
Lexington, Kentucky
Director: Dr. Michelle Marie Martel, Professor of Psychology
Lexington, Kentucky
2016
Copyright © Bethan Anne Roberts 2016

	
  

i	
  

ABSTRACT OF DISSERTATION

OVARIAN HORMONES, ADHD, RISK-TAKING, & IMPULSIVITY
Attention-Deficit/Hyperactivity Disorder (ADHD) is a highly impairing disorder of
inattention, hyperactivity, and impulsivity that is more frequently diagnosed in males
versus females at a ratio of 3:1. However, females with the disorder become highly
impaired during adolescence, perhaps due to the onset of cycling ovarian hormones at
puberty. The present study empirically assessed the role of the major female sex
hormones, estrogen and progesterone, in the presentation of ADHD symptoms,
impulsivity, and associated risk-taking behaviors (e.g., risky sex, substance use and
abuse) in a non-clinical sample of young adult women. 32 healthy young adult women
who were screened for hormonal conditions and medication use completed an initial
laboratory visit during which measures of impulsivity and ADHD symptoms were
collected. Each morning for 35 subsequent days, participants’ hormones were measured
via passive drool saliva samples, and participants responded to a brief online survey
regarding substance use and sexual behaviors for the last 24 hours. Each evening,
participants completed online questionnaires regarding ADHD symptoms. Results
showed that ADHD symptoms were most pronounced when estrogen was low; this
association manifested (1) between women, with lower average estrogen across the entire
cycle predicting higher ADHD symptoms, and (2) within women, with lower-thanaverage levels of estrogen during periods of higher-than-average progesterone predicting
higher ADHD symptoms two days later, consistent with a post-ovulatory, luteal phase
effect of estrogen. Moderation analyses revealed that these within-person effects of
ovarian hormones were significant only among women with high negative or positive
urgency (emotion-related impulsivity) or high sensation seeking. With regard to alcohol
use, within-person results were somewhat different; higher-than-average within-person
estrogen was associated with higher likelihood of drinking and binge drinking on the
following day, and this was true only during periods of lower-than-average progesterone,
consistent with a pre-ovulatory, follicular phase effect of estrogen. These results have
implications for the conceptualization of ADHD and associated risk-taking behaviors
such as drinking, including personalization of treatment approaches for women.
KEYWORDS: ADHD, Estrogen, Progesterone, Menstrual Cycle, Ovarian Hormones
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CHAPTER ONE: INTRODUCTION
Background
	
  
Attention-Deficit/Hyperactivity Disorder (ADHD) is a common and highly
impairing childhood neurodevelopmental disorder (APA, 2013; Bernfort, Nordfeldt, &
Persson, 2008; Pelham, Foster, & Robb, 2007, Polanczyk, de Lima, Horta, Biederman, &
Rohde, 2007) that often persists into adolescence and adulthood (Faraone & Biederman,
2005; Kessler et al., 2006). The prevalence rate of ADHD in adults is thought to be
between 3 and 5% (Faraone & Biederman, 2002; 2005; Kessler et al., 2006; Wilcutt,
2012). Adults with ADHD are at an increased risk for engaging in behaviors with
negative outcomes and high societal cost, such as substance abuse, promiscuous sexual
activity, and increased vehicular accidents, and are at increased risk for anxiety and mood
disorders (Bauermeister et al., 2007; Barkley, 2006; Hosain, et al., 2012; Loe & Feldman,
2007; Flory, Molina, Pelham, Gnagy, & Smith, 2006; Wehmeier, Schacht, & Barkley,
2010). One of the most noted features of ADHD is that it is more frequently diagnosed in
male children at a ratio of 3:1; yet females with the disorder are often particularly highly
impaired beginning during adolescence and into adulthood (Lahey, et al. 1994),
exhibiting such negative outcomes as poor self esteem, increased rates of anxiety and
depression, and unplanned pregnancies (Biederman et al., 1999; Hosain, et al., 2012;
Quinn, 2005, Robison et al., 2008). Further, there appear to be sex differences in
symptom expression such that males with ADHD are more likely to exhibit
hyperactivity-impulsivity and comorbid disruptive behavior disorders during childhood,
while females with ADHD are more likely to exhibit inattention and comorbid depression
during adolescence (Gaub & Carlson, 1997; Gershon & Gershon, 2002).
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Yet, mechanisms of sex differences in symptom expression and comorbidity
remain unknown, despite the fact that changes in sex, or gonadal hormones, during the
prenatal period and adolescence may likely play a role. Initial work, in fact, suggests a
role for prenatal testosterone exposure and ADHD (Martel, 2009; McFadden et al., 2005;
Roberts & Martel, 2013). Such work suggests that known markers of symptoms and
pathways to ADHD such as cognition and traits can help shed light on hormonal
mechanisms. The current project focuses on ADHD symptoms, specific markers of
disorder including cognition (executive function), risk-taking (drug abuse), and
impulsivity (urgency), and circulating hormones during adolescence and young adulthood
as a particularly understudied and yet critically important developmental risk factor for
ADHD. The only existing work on hormonal associations with ADHD symptoms in
adulthood relied on case studies which suggest that ADHD symptoms may fluctuate
across the menstrual cycle, worsening the week before menstruation (when both estrogen
and progesterone are declining; Quinn, 2005) and with symptom relief during pregnancy,
a time of dramatically increased estrogen and progesterone (Nadeau & Quinn, 2002).
Yet, no work to date has directly examined hormone levels themselves and their
relationship to ADHD symptoms in groups of women, the goal of the current project.
Ovarian Hormonal Effects
	
  
Given that females with ADHD exhibit striking impairment beginning during
adolescence, dramatic rises and fluctuations in sex hormones at puberty might play a role
in this phenomenon. Beginning just before puberty, which typically occurs between 9 and
14 in human females (Norman & Litwack, 1997), both estrogen (E2) and progesterone
(P4) rise and then begin to fluctuate across the monthly female reproductive cycle, as
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shown in Figure 1 (Norman & Litwack, 1997). Generally speaking, in a typical 28-day
cycle, E2 and P4 are both low during the week or so following the onset of menstruation,
known as the early follicular phase. While P4 remains low throughout the remainder of
the follicular phase, about eight days after the onset of menses, E2 begins rising steadily,
reaching its peak around ovulation (occurring, on average, around 14 days prior to the
onset of the next menses), alongside a more notable peak in lutenizing hormone, which
marks the beginning of the luteal phase (Mishell et al., 1971; Norman & Litwack, 1997;
see Figure 1). Notably, most variation in cycle length is attributable to the follicular phase
of the menstrual cycle, with the luteal phase demonstrating much greater stability (~14
days). For example, stress can lengthen the follicular phase of the cycle, while the luteal
phase of the cycle is much more consistent in length (Fehring, Schneider, & Raviele,
2006; Norman & Litwack, 1997).
This second half of the cycle (after ovulation) is called the luteal phase.
Immediately following ovulation, E2 first declines rapidly before exhibiting a second
smaller rise along with increasing P4 levels, which reach an all time high around midluteal phase. At the end of the luteal phase, both E2 and P4 decline rapidly a few days
before the onset of the next menses (Norman & Litwack, 1997). Yet, it cannot be
stressed enough that this typical pattern can vary greatly within women and between
women on a month-to-month basis (Treloar, Boynton, Behn & Brown, 1967). For
example, women exhibit striking variability in their levels of E2 and P4, as well as in the
length of their cycle, even from month to month (Chatterton et al., 2005; Fehring,
Schneider, & Raviele, 2006). In addition, individual women exhibit striking variation in
their levels across the menstrual cycle with inter- and intra-person variation in the
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magnitude of surges and declines (Chatterton et al., 2005). Further, after puberty, the
menstrual cycle can take several years to become the fairly regular average of 28 days it
is for most adult females (Norman & Litwack, 1997; Treloar, Boynton, Behn & Brown,
1967).
Cyclical hormonal patterns and levels change across development. Before
puberty, gonadal hormones including E2 and P4, as well as testosterone, remain fairly
low and static (Norman & Litwack, 1997). However, as puberty approaches, levels of
gonadal hormones rise and, in women, begin to fluctuate in the cyclical manner described
above (Norman & Litwack, 1997). Yet, this regular pattern often does not stabilize for
several years. Furthermore, pregnancy, menopause, endocrine disease, use of oral
contraceptives, use of steroid medication, body mass index, and even stress can impact
hormone levels (Dobson & Smith, 2000; Gaspard et al., 1983; Lukanova et al., 2004;
Nelson, 2011; Norman & Litwack, 1997; Pastor, Griffin-Korf, Aloi, Evans, & Marshall,
1998; Van der Vange, Blankenstein, Kloosterboer, Haspels, & Thijssen, 1990; Weiner,
Primeau, & Ehrmann, 2004).
Yet, hormone levels and the more typical study of phase effects appear to be
strikingly important for understanding female mood (which has been heavily studied;
Eisenlohr-Moul, DeWall, Girdler & Segerstrom, 2015; Nelson, 2011; Payne, 2003;
Steiner, Dunn, & Born, 2003; Vesco, Haney, Humphrey, & Nelson, 2007; Walf & Frye,
2006; Weiner, Primeau, & Ehrmann, 2004), as well as other affective processes,
including impulsivity (Klump et al., 2014; Rosenblitt, Soler, Johnson and Quadagno,
2001). Yet, perhaps because of the complexity of such effects, hormonal influences on

	
  

4	
  

these constructs remain relatively understudied and have never been directly studied in
relation to ADHD in particular (Nussbaum, 2012).
Ovarian Hormonal Associations with Problems Related to ADHD
The fact that circulating hormone levels are dramatically understudied in relation
to ADHD symptoms in females is particularly surprising given their known roles in
associated processes such as executive function (EF), risk-taking, and response to
psychostimulants. Deficits in executive function (e.g. problem-solving to achieve a future
goal, including working memory, inhibition) are commonly associated with ADHD,
occurring in at least 50% of individuals with an ADHD diagnosis (Willcutt, Doyle, Nigg,
Faraone, & Pennington, 2005). Higher levels of both E2 and P4 have been individually
linked to enhanced EF and attention (e.g., Davis & Nolen-Hoeksema, 2000; Hatta &
Nagaya, 2009; Segerstrom, Roach, Evans, Schipper, & Darville, 2010). Several aspects
of EF appear to be improved when E2 and P4 levels are high (Gogos, 2013; Howard,
Gifford, & Lumsden, 1988; Jacobs & D’Esposito, 2011; Lord & Taylor, 1991; Rosenberg
& Park, 2002; Segal, 2012; Vranic ́ & Hromatko, 2008; Solís-Ortiz & Corsi-Cabrera,
2008; Solis-Ortiz, Guevara, & Corsi- Cabrera, 2004). For example, a study of naturally
cycling young adult women (age 18-28), suggested a positive association between the
follicular phase (when E2 is typically high) and executive functions that are “typical
female” strengths. More specifically, women in the follicular phase demonstrated better
performance on tasks of verbal implicit memory and verbal fluency, but worse
performance on tasks involving mental rotations and perceptual priming (Maki, Rich &
Rosenbaum, 2002). Thus, E2 appears to facilitate most types of EF.
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Studies also demonstrate worsening memory and sustained attention during
menopause (Frankiewicz & Cutler, 2000; Schmidt et al., 1996), a period characterized by
a significant decrease in and destabilization of ovarian hormones. Likewise, a study in
post-menopausal elderly women demonstrated that low doses of E2 might improve brain
function efficiency during the tasks of sustained attention (Stevens, Clark & Prestwood,
2005). Finally, experimental administration of either E2 or P4 following pharmacological
hormone suppression normalizes neural activity associated with executive functioning
(Berman et al., 1997). Thus, overall, results are consistent with the idea that high levels
of E2 are associated with better EF, including working memory and attention, two EFs
that appear to be related to symptoms of ADHD.
In addition to the higher prevalence of EF deficits, individuals with ADHD also
engage in higher levels of risk-taking than their peers (which in adulthood often
manifests as substance abuse and risky sexual behaviors (Barkley, Murphy, & Fischer,
2010; Biederman et al., 2002; Disney et al., 1999; Wilens, Spencer, & Biederman, 1995).
In some studies, cyclical “lows” of both E2 and P4 (measured via cycle phase and
hormone levels) appear related to increased risk for alcohol and tobacco abuse
(Carpenter, Upadhyaya, LaRowe, Saladin, & Brady, 2006; Evans & Levin, 2011; Epstein
et al., 2006; Franklin et al., 2004, 2008; Pastor & Evans, 2003; Schiller, Saladin, Gray,
Hartwell, & Carpenter, 2012). Yet, the subjective effects of stimulants (e.g. cocaine,
methamphetamine) appear to have the opposite pattern of association with hormones,
such that women report greater subjective effects of stimulants during the follicular phase
(when E2 is rising and P4 is at low, at almost undetectable levels) compared to the luteal
phase, when P4 is high and E2 is moderate (Sofuoglu, Dudish-Poulsen, Nelson, Pentel &
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Hatsukami, 1999; Terner & de Wit, 2006). Pre-treatment with E2 also increases some of
the subjective effects of stimulant medications (Justice & deWitt, 1999; 2000, White,
Justice & de Wit, 2002), whereas high levels of P4 and administration of P4 attenuate the
subjective effects of stimulants, minimizing the effects of E2 on stimulant effects during
the luteal phase (Evans, 2007; Justice & deWitt, 1999). In line with hormonal effects on
alcohol and nicotine use, lower E2 has also been associated with increased risk-taking as
measured by monetary risk tasks, trust of strangers during an investment game, and
measures of real-life risky behaviors, all of which demonstrated that women were less
cautious (i.e., took more risks) during phases when levels of E2 were low, as measured
by counting cycle days (Ball et al., 2013; Broder & Hohmann, 2003; Kaighobadi &
Stevens, 2013).
Taken together, these studies suggest that low levels of E2 may be risky for
increased use of and cravings for substances such as alcohol. Yet, the effects of other
stimulants (e.g. cocaine, amphetamines) appear to be enhanced by E2 such that they are
more rewarding to utilize when E2 is high and P4 is low (i.e. the follicular phase). Due to
the higher incidence of risk-taking and substance use among women with ADHD, it is
possible that women at risk for the disorder have lower average levels of E2 that put them
at risk for use of alcohol. Thus, lower average E2 may represent a pathway to both
substance use and ADHD symptoms in some women.
ADHD Heterogeneity
	
  
Recent theory of ADHD defines it as a disorder of disinhibition (Barkley, 1997;
Nigg, 2001), and impulsivity is a core component based on ADHD diagnostic criteria.
Yet, one of the most striking features of the disorder is its heterogeneity, which is
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currently described using three subtypes, or presentations. Likewise, recent theory of
ADHD suggests multiple pathways to the disorder (Nigg, Goldsmith, & Sachek, 2004;
Sonuga-Barke, 2005), with continuous symptom dimensions perhaps best supported
(Haslam et al., 2006; Larsson, Anckarsater, Råstam, Chang, and Lichtenstein, 2012;
Marcus & Barry, 2011). In adulthood, one potentially particularly promising way of
doing this is by focusing on impulsivity, which seems to be particularly prominent in
adulthood (Barkley, Murphy, & Fischer, 2010). Notably, conceptualization of impulsivity
has advanced in recent years (Lynam, Smith, Whiteside, & Cyders, 2006; Smith et al.,
2007).
A handful of studies on such conceptualizations of impulsivity in adults with
ADHD suggest associations with Lack of Perseverance (inability to remain with a task
through completion), Negative Urgency (negative affect-driven rash action), and Lack of
Planning (action without careful thinking; Miller et al., 2010; Pedersen et al., 2016;
reviewed by Berg, Latzman, Bliwise, & Lilienfeld, 2015). Sensation Seeking (tendency
to seek adventure) may be more specifically associated with hyperactivity-impulsivity
(Lopez et al., 2015). Further, Urgency, Sensation-Seeking, and Lack of Planning appear
to explain associations between ADHD and substance use (Pedersen et al., in press;
Roberts et al., 2014). These studies suggest that trait impulsivity appears to be related to
ADHD, and those who are high in certain forms of trait impulsivity may be more likely
to experience risk-taking behaviors (e.g., substance use). According to an interactional
perspective on personality (Endler & Parker, 1992), impulsive action (i.e. risk taking
behaviors) are dependent on an individual’s personality in addition to interactions with
other factors, including social, environmental or biological factors (Endler & Parker,
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1992). Therefore, studies examining hormonal associations with ADHD in young adult
women may need to pay particular attention to impulsivity as a moderator of hormonal
effects since these effects may interact and effects may be particularly striking for young
women high in trait impulsivity.
Goals of the Present Study
	
  
To recap, although lower E2 appears to be associated with worse EF and more
risk taking (e.g., substance use), no empirical work to date has directly examined the role
of circulating E2 in relation to ADHD symptoms and associated markers. Further,
specific types of trait impulsivity may help explain heterogeneity within ADHD in adults;
yet, thus far, these ideas have not been examined.
The present study sought to examine the association between ovarian hormone
levels, ADHD symptoms, and risk-taking behaviors (i.e., substance use), and to explore
whether associations between ovarian hormones and ADHD symptoms and risk-taking
behaviors are moderated by trait impulsivity. Based on prior work suggesting that higher
E2 has positive effects on EF and decreases risk for more common forms of substance
use (i.e., alcohol), it was hypothesized that, 1) between-women, lower average E2 across
the entire menstrual cycle (i.e. higher overall recent exposure to E2) would be associated
with greater ADHD symptoms and risky behaviors, 2) lower-than-average (withinperson) levels of E2 would be associated with increases in ADHD symptoms and risky
behaviors, and that 3) lower-than-average (within-person) levels of E2 would be more
strongly associated with increased ADHD symptoms and risk-taking for those with
higher levels of trait impulsivity. Additionally, given the potential for interactive effects
of E2 and P4 (Klump et al., 2008; 2013; Eisenlohr-Moul et al., 2015), P4 was included as
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an exploratory variable, and examined as a moderator of E2 effects. Finally, phase effects
were also examined in order to more easily compare study results to previous studies that
utilized cycle phase.

Figure 1. Typical representation of expected E2 and P4 levels across the cycle (HaimovKochman & Berger, 2007). The boxes indicate periods of the cycle hypothesized to
exhibit increases in ADHD symptoms and risk-taking behaviors.
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CHAPTER TWO: METHODS
Overview of Study Design
	
  
The study design was short-term longitudinal. Participants completed a screening
visit to determine study eligibility. The women eligible to participate in the current
project subsequently completed 35 sequential days of in-home data collection lasting 3045 minutes each day. Hormones were assayed every other day, resulting in an average of
17 observations per woman.
Participants
	
  
Participants were a non-clinical sample of 32 naturally-cycling young women
between the ages of 18 and 22 (M = 19.43, SD = 1.38) that were undergraduates recruited
from the University of Kentucky Psychology Department subject pool and young women
from the community recruited via posted flyers. The participants’ ethnic background
broadly matched that of the surrounding community; 70.6% of the sample identified as
Caucasian, 17.6% as African American, and 11.8% as another ethnic minority.
Procedure
Screening and Initial Lab Visit. All participants completed one in-lab screening
visit where they provided informed consent via IRB-approved procedures. The 32
eligible females completed 35 sequential days of follow-up data collection at home.
Study eligibility was assessed at the initial screening visit. All participants completed the
Screening and Medical History Form (detailed below), and a measure of study eligibility,
with a trained study staff member. Participant’s height and weight were also measured
since body mass index has been demonstrated to have an effect on circulating levels of
sex-steroid hormones (Lukanova et al., 2004; BMI Mean = 24.37, SD = 6.33). Finally,
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participants completed measures of trait impulsivity, ADHD symptoms, and executive
functioning at this initial visit (detailed below).
To be eligible for the study, participants had to be female and between 18 and 24.
Exclusionary criteria included primary sensorimotor handicap, neurological disorder
(e.g., seizure disorders, brain tumor, cerebral palsy, hydrocephalus, head injury with loss
of consciousness), known pervasive developmental disorder (i.e., autism, Asperger’s,
Rett’s, childhood disintegrative disorder), reported psychosis (i.e., schizophrenia,
hallucinations, delusions), diagnosed intellectual disability, known hormonal
abnormalities (e.g., Polycystic Ovarian Syndrome, thyroid conditions), including
irregular cycles (i.e., cycles shorter than 21 days or longer than 35 days or fluctuating by
more than 10 days across cycles, per self report), and current medical use of hormonal
preparations (e.g., oral contraceptives, steroid-based medications), psychostimulants, or
antipsychotic medications. Other medication use was measured in an open-ended
manner; three women reported using prescribed Selective Serotonin Reuptake Inhibitors
(SSRIs). However, SSRI use was not associated with outcomes or average hormone
levels across the cycle (all p’s < .34). Participants who met study exclusionary criteria
were invited to complete the 35-day study. Forty-eight women were eligible and began
data collection. However, 23% (N=11) discontinued participation during the study and
10% (N=5) completed less than 50% of data collection, leaving a final sample size with
usable data of 32 women.
Eligible and interested female participants were sent home with a packet of data
collection materials so they could collect data every day for the following 35 days.
Detailed instructions on at-home data collection were provided verbally and in writing,
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and participants were provided with the telephone number and email address of a trained
research assistant in case they had any questions. They also provided a telephone number
and email address so that they could receive daily reminders about data collection and
links to morning and evening surveys throughout the 35 days. Every morning,
participants provided saliva samples (described below), and responded to a short
questionnaire about psychotropic medication use and food intake. All participants
reported taking some form of medication over the course of the study. The most common
included over-the-counter medications for pain, gastrointestinal distress, cold and flu, and
allergies. None of the participants reported eating immediately upon waking, suggesting
that saliva collection directions were followed.
At this time, participants also completed a measure of drinking, described below.
In the evening after 5pm, they were instructed to follow an email link to a secure website
to complete 30-45 minutes of questionnaires (described below) which are time- and datestamped so accuracy of data collection could be monitored. Timestamps suggested that
data were collected appropriately (e.g. morning surveys completed in morning and
evening surveys completed same-day after 5pm). At the end of the 35 days, study staff
contacted participants and arranged for a time for them to return their frozen saliva
samples to the laboratory for storage in an -80 degree freezer. Participants who completed
any data collection received $50 compensation, those who completed >50% of the data
received $75, and those who completed all data collection received $100. Following the
end of data collection, saliva samples were sent in bulk to the Center for Clinical and
Translational Science (CCTS) on the University of Kentucky campus for at-cost assaying
with well-established and reliable assays (described below).
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Measures
	
  
ADHD Symptoms. Participants completed the Current ADHD Symptoms Scale
(CSS): Self-report, a symptom checklist for ADHD, Oppositional-Defiant Disorder
(ODD), and Conduct Disorder (CD) symptoms and associated impairment (Barkley &
Murphy, 2006) at the screening visit and for the next consecutive 35 days. Symptom
counts were used for analysis rather than diagnosis, as the sample was communityrecruited and research indicates that ADHD is best represented as a continuum (vs.
category; Barkley, 2006; Haslam et al., 2006; Marcus & Barry, 2011). Second reporter
responses for childhood symptoms were received for 34% of participants (N=11), and
indicated that only one participant experienced a clinically significant number of ADHD
symptoms (5 inattentive and 3 hyperactive-impulsive symptoms) during childhood.
Second reporter responses for current symptoms were received for 41% of participants
(N=13) and reports of both childhood and adult symptoms were received from 28% of
participants (N =9). Based on self and second reporter responses, none of the participants
met DSM-5 criteria for ADHD. Total possible daily (state) reported ADHD symptoms
ranged from 0 to 18 (M = .52, SD = 1.40; α = .80). Total possible Hyperactive-Impulsive
symptoms ranged from 0 to 9 (M = .32, SD = .66; α = .66), and possible Inattentive
symptoms ranged from 0 to 9 (M = .20, SD = .65; α = .72). Data screening revealed that
symptoms were right skewed so log transformations were carried out and were successful
in producing normal residuals for all analyses.
Impulsivity. At the initial visit, participants completed the UPPS-P Trait
Impulsivity Scale, a 59-item questionnaire that assesses five components of trait
impulsivity (i.e. Positive Urgency [positive affect-driven rash action], Negative Urgency
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[negative affect-driven rash action], Lack of Planning [action without careful thinking],
Lack of Perseverance [inability to remain with a task through completion], and Sensation
Seeking [tendency to seek adventure; Whiteside & Lynam, 2001]). The scale has
demonstrated reliability and validity for use in assessing young adults (Lynam et al.,
2006; Cyders et al., 2007). In the current sample, Lack of Perseverance exhibited fair
reliability (α = .56) and Lack of Premeditation, Negative Urgency, Positive Urgency and
Sensation Seeking exhibited good reliability (α = .82-.93).
Risk-taking Behaviors. Each morning, participants reported detailed information
about sexual behaviors (new sexual partners), drug use (marijuana and other recreational
drugs), and the number of units of alcohol that they had consumed in the past 24 hours
using an adaptation of the Timeline Followback Interview (Sobell & Sobell, 1992; 1994).
This interview has good reliability and validity in this population (Tonigan, Miller, &
Brown, 1997) and for this purpose (Del Boca, Darkes, Greenbaum, & Goldman, 2004).
Due to the limited frequencies of drug use (17 reports, .4% of days) and risky sex (3
reports, .01% of days) in the sample, it was not possible to examine these outcomes.
Units of alcohol were defined as one shot, one beer, or one glass of wine. Two daily
binary outcomes were defined from this response: first, whether or not the woman drank
alcohol at all, and second, whether the woman drank 4 or more drinks (binge drinking).
Although binge drinking has been defined in a variety of ways, this corresponds to the
definition provided by the CDC (http://www.cdc.gov/alcohol/fact-sheets/bingedrinking.htm). Because drinking was expected to follow a weekly cycle in which alcohol
use is substantially higher on Thursday through Saturday, with intermediate levels of
drinking on Sunday, and much lower levels of drinking Monday through Thursday (Del
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Boca, Darkes, Greenbaum, & Goldman, 2004), day of week was also examined in
analyses involving drinking utilizing a dichotomous predictor of weekend status (where
Thursday through Sunday = 1).
17β-Estradiol and Progesterone. Saliva samples were collected via passive
drool by participants in the morning thirty minutes after waking and were subsequently
frozen. Participants were instructed not to eat, drink, brush teeth, or smoke before saliva
collection. No participant reported violation of this morning protocol in daily diaries.
Samples from every other day were analyzed due to cost. Serum E2 (pg/mL) and P4
(pg/mL) were determined using enzyme immunoassay kits available through Salimetrics
and assayed through campus Clinical Center for Translational Science. For E2, the
Salimetrics 17β-Estradiol immunoassay kit had a sensitivity of 0.1 pg/mL and high
precision (% coefficient of variation ranging from .7 to 14.5). For P4, the Salimetrics
immunoassay kits had a sensitivity of 5 pg/mL (from 0) and precision of percent
coefficient of variation between 1.05 and 14.8. All participants showed peak P4 levels
consistent with an ovulatory cycle (Howards et al., 2009). Finally, E2 and P4 generally
showed expected trajectories across the menstrual cycle such that E2 demonstrated a
midcycle peak and secondary peak during the midluteal phase, and P4 was low during the
follicular phase and peaked during the luteal phase.
Menstrual Cycle Phase Coding. First, we coded the follicular, midluteal, and
premenstrual phase menstrual cycle days using methods described by Edler, Lipson, &
Keel (2007). The first day of menses was coded as 1; from this day 1, cycle day was
counted backward to -15, and forward to +10. There was no day 0. Cycle phases were
coded as Follicular (days +3 to +7), Midluteal (-9 to -5) and Premenstrual (-3 to +1). In
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addition to these traditional menstrual cycle coding methods, we created an additional
cycle phase variable to further differentiate pre-ovulatory and post-ovulatory phases. To
create this variable, we identified four pre-E2 peak and four post-E2 peak days: after
identifying the ovulatory E2 peak, the day of the ovulatory E2 peak and the three days
prior comprised the “preovulatory” phase, while the four days after the ovulatory peak
comprised the “postovulatory” phase. Therefore, five total phases were coded, with no
overlap: Follicular, Preovulatory, Postovulatory, Midluteal, and Premenstrual.
Analytic Plan
	
  
Operationalization of Predictor and Outcome Variables. Each participant had
two E2 variables and two P4 variables: (1) Between-Person Variables: the person’s
average levels of E2 and P4 across all samples (“trait” variance in each hormone across
one menstrual cycle) and (2) Within-Person Variables: the standardized deviation of
today’s E2 and P4 values from a woman’s average levels of E2 and P4 across all samples
(i.e., today’s hormone value minus the “person average” for that hormone, divided by the
person’s standard deviation for that hormone; see Klump et al., 2008). The latter
standardized deviation reflects fluctuations in E2 and P4 relative to the person’s own
average level and one’s own typical degree of variability and was the central withinperson predictor. Hormones were also lagged such that hormonal predictors of today’s
ADHD outcomes represented hormone levels two days ago, and hormonal predictors of
today’s drinking outcomes (analyzed in the subsample of 22 women reporting drinking
any alcohol) represented levels one day ago. We made this decision because participants
responded to questions about their drinking “over the last 24 hours” during morning
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surveys and to questions about ADHD symptoms and impulsivity about “today” during
evening surveys. All continuous between-person predictors were standardized.
Multilevel Logistic Models. Data were analyzed using multilevel models in SAS
PROC MIXED and SAS PROC GLIMMIX in which repeated daily measures (outcomes,
hormones) were nested within women. Multilevel models utilize all available data with
no listwise deletion and accommodate missing data using maximum likelihood
estimation. In daily models, day-level hormonal predictors were person-standardized
around each woman’s average and standard deviation to isolate the within-person
component and create a averageingful scale for estimates.
To evaluate the unique contributions of between- and within-person variance in
ovarian hormones to ADHD symptoms, normal multilevel models were utilized
predicting daily outcomes (ADHD symptoms and drinking) in SAS PROC MIXED. In
each of these multilevel models, predictors were: 1) standardized BMI as a person-level
covariate, 2) one’s average E2 (across all observations), 3) one’s average P4 (across all
observations), 4) person-standardized E2 two days before the outcome, 5) personstandardized P4 two days before the outcome, and 6) the interaction of personstandardized E2 and P4. Both between-person predictors (one’s average E2 and P4) and
within-person predictors (person standardized E2 and P4 at the current assessment point)
were entered into the same model (see tables 3.1-3.5).
In order to explore whether person-standardized ovarian hormones (fluctuations
relative to one’s individual average and SD) were more strongly associated with daily
ADHD symptoms for those with higher trait levels of impulsivity, multilevel regression
models were again utilized predicting each outcome from 1) standardized BMI as a
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covariate, 2) one’s average levels of E2 and P4 (as a control variables), 3) personstandardized recent E2 and P4, and 4) their interaction, 5) trait levels of impulsivity, and
6) the interactions of all hormone variables with trait impulsivity.
Drinking outcomes were analyzed in logistic multilevel models in SAS PROC
GLIMMIX. Daily drinking outcomes were predicted from 1) standardized BMI and legal
drinking status (0 = Underage 1 = Legal Age) as person-level covariates, 2) dichotomous
weekend status (Thursday-Sunday = 1; Monday-Wednesday=0, 3), average E2 and P4
(across all observations), 4) yesterday’s person-standardized levels of E2, 5) yesterday’s
person-standardized levels of P4, 6) their interaction, and 7) the two- and three-way
interactions of steroid levels with weekend status.
Statistical Power. For all analyses, power was adequate (.8) to detect moderate
effect sizes (d =.07-.09; Klump et. al., 2013) based on the current sample size (N =32). In
order to reach power to detect small effect size (d=.02), 2000 observations from 145
women would be needed. For ADHD outcomes (full sample; normal multilevel models),
intraclass correlation coefficients for both daily hyperactive/impulsive symptoms (ICC =
.27) and daily inattentive symptoms (ICC = .36) indicated that the majority of the
variance in ADHD symptoms was at the within-person level, leading to an adjusted N of
95 observations for the hyperactive/impulsive outcome, and an adjusted N of 76
observations for the inattention outcome. The smallest detectible effect sizes, assuming a
normally distributed outcome, for a cross-level interaction predicting daily
hyperactivity/impulsivity (f squared = .091) and daily inattention (f squared = .085)
indicated sufficient power to detect conventionally small-to-medium interactive effects of
UPPS traits and within-person hormone variables.
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For drinking outcomes, intraclass correlation coefficients for both daily drinking
(ICC = .15) and daily binge drinking (ICC = .23) also indicated that the majority of the
variance in drinking was at the within-person level, leading to an adjusted N of 140
observations for the daily drinking outcome, and an adjusted N of 95 observations for the
daily binge drinking outcome. Detectible ranges of effect sizes (in this case, odds ratios)
in logistic models predicting drinking (ORs below .58 and ORs above 1.71) and binge
drinking (ORs below .51 and ORs above 1.94) indicated sufficient power to detect
conventionally small-to-medium main effects of a within-person hormonal predictor in a
model in which other predictors account for 25% of the variance in drinking.
CHAPTER THREE: RESULTS

	
  
Descriptive Analyses
	
  
The full sample (N=32) included 1058 response days, with 476 outcome days
included in analyses (i.e., days with nonmissing lagged hormonal predictors). 22 women
in the sample reported alcohol use with similar demographics as the full sample. The
subsample included 707 total days, with 352 outcome days included in analyses (i.e.,
days with non-missing lagged hormonal predictors). Among women who reported
drinking, there were 97 total daily drinking reports (13.7% of days range = 0-15 days of
drinking) and 31 binge drinking reports (4.3% of days).
Association of Hormone Averages, Trait Impulsivity & Trait ADHD Symptoms
Despite the small degree of between-person variance noted in ADHD symptoms,
spearman rank partial correlations examined the associations of average ADHD symptom
reports with average levels of E2 and P4 across the data collection period (controlling for
both age and BMI). Higher total exposure to E2 and P4 were associated with lower
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average inattention. E2 exposure, but not total P4 exposure, was associated with lower
average hyperactivity/impulsivity. Average E2 was uncorrelated with any impulsivity
measures, but total P4 exposure was negatively associated with Positive Urgency,
Sensation Seeking, and Lack of Premeditation.
Effects of E2 and P4 on ADHD Symptoms
	
  
The model included both between-person and within-person ovarian hormone
variables as predictors of daily ADHD symptoms (Inattentive, Hyperactive-Impulsive,
and total ADHD symptoms). In other words, three separate models were conducted in
which these different symptom domains were independently predicted as a function of
one’s average levels of both E2 and P4 across the menstrual cycle, from women’s personstandardized E2 and P4 fluctuations around their own average, and the within-person
interaction of E2 and P4. Model effects reported throughout this manuscript were not
substantially altered in significance or effect size when random effects of within-person
hormonal predictors were added to the multilevel models. However, these random effects
of within-person hormonal predictors did not significantly improve model fit (as
evaluated using a likelihood ratio test) and were therefore dropped from the models.
Results of this model are presented in Table 3.1 and are summarized in the paragraphs
that follow.
There was just one significant between-person effect of average hormones on
ADHD symptoms. As hypothesized, lower average E2 across the month predicted higher
average endorsement of daily hyperactive-impulsive ADHD symptoms across the month.
Within a given person, person-standardized E2 and P4 interacted to predict daily total
ADHD symptoms in total, including both inattention and hyperactivity-impulsivity. The
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pattern of this interaction was identical across these three outcomes, and each of these
interactions are depicted in Figure 3.1. When P4 was higher than usual, lower personstandardized E2 was associated with more current total ADHD symptoms (γ = -.08, SE =
.03, t(393) = -2.77, p = .005; when P4 is +1 person-SD above the person average, a +1
person-SD above one’s person average E2 corresponds to an average decease of .08 in
ADHD symptoms), hyperactive/impulsive symptoms (γ = -.06, SE = .02, t(390) = -2.93, p
= .003; when P4 is at +1 person-SD above the person average, a +1 person-SD above
one’s person average E2 corresponds to an average decrease of .06 in
hyperactive/impulsive symptoms), and inattentive symptoms (γ = -.05 SE = .02, t(424) =
-1.99, p = .049; when P4 is at +1 person-SD above the person average, a +1 person-SD
above one’s person average E2 corresponds to an average decrease of .05 in inattentive
symptoms), consistent with a post-ovulatory, luteal phase effect of E2. The effects of
person-standardized E2 were not significant when P4 was lower than usual (all p’s >
.34). Phase analyses showed similar results, in that inattentive symptoms were
significantly higher during the postovulatory period than follicular phase (p= .03; see
Figure 3.2). Although statistically significant, these unmoderated (average) hormonal
effects are quite small when considered in light of the possible ranges of the outcomes (09 for each subscale and 0-18 for the total score).
Moderation of Hormone Effects by Trait Impulsivity
	
  
Negative and Positive Urgency. Both Positive and Negative moderated average
E2 and the interaction between recent E2 and P4 predicting ADHD outcomes. There was
a significant interaction between both types of Urgency and average levels of E2
predicting all ADHD symptoms outcomes and between both types of Urgency and the

	
  

22	
  

interaction of recent levels of E2 and P4 predicting ADHD outcomes; each of these
interactions took the same form, which are depicted in Figures 3.3 through 3.7.
However, further examination revealed that these effects were significant only for those
women who were high in either Positive or Negative Urgency (all p’s < .016). Results of
analyses probing these interactions revealed that, at high levels of Positive or Negative
Urgency, lower average E2 across the cycle was associated with increased ADHD
symptoms. None of these effects of E2 were significant among women low in Negative
Urgency (all p’s > .39) or low in Positive Urgency (all p’s > .59).
To further decompose these three-way interactions, we tested the simple effects of
recent E2 on each outcome at both lower-than-average (-1 person-SD below the person
average of P4) and higher-than-average (+1 person-SD above the person average of P4)
P4 among women high (+1 SD) in trait Urgency. The simple effects of lower-thanaverage E2 leading to higher ADHD symptoms were significant only at higher-thanaverage P4 (e.g., the luteal phase; all p’s < .025). This was true for both Negative and
Positive Urgency. At lower-than-average P4 (i.e., the follicular phase) among women
with high Positive or Negative Urgency, simple effects of recent E2 were not significant
(all p’s < .27).
Phase analyses revealed that for those high in Negative Urgency, inattentive
symptoms peaked in the post-ovulatory phase relative to the follicular, pre-ovulatory
midluteal phase and premenstrual phases (see Figure 3.8). Similarly, for those high in
Positive Urgency, inattentive and hyperactive-impulsive symptoms peaked during the
postovulatory phase (see Figure 3.9).
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Sensation Seeking. There were no significant interactions between Sensation
Seeking and average levels of E2 or P4 predicting any ADHD symptoms outcomes.
However, there were significant interactions between Sensation Seeking, Recent E2, and
Recent P4 predicting all ADHD symptoms; each of these interactions are presented in
Figure 3.10. The two-way interaction between recent E2 and recent P4 was significant
only among women who were high (+1 SD) in Sensation Seeking. The three-way
interaction was explored in the same manner described above.
The simple effects of lower-than-average E2 leading to higher ADHD symptoms
were significant only at higher-than-average P4 (e.g., the luteal phase) among women
with high Sensation Seeking. At lower-than-average P4 (i.e., the follicular phase) among
women with high Sensation Seeking, simple effects of recent E2 were not significant (all
p’s < .15).
Phase analyses revealed a decrease in inattentive and hyperactive-impulsive
symptoms during the pre-ovulatory phase for those high or low in Sensation Seeking;
however, symptoms were lowest during the premenstrual phase than any other phase.
There was also a peak in symptoms during the post-ovulatory phase for those high in
Sensation Seeking (see Figure 3.11).
Lack of Premeditation and Lack of Perseverance. Lack of Premeditation did
not moderate any hormone effects on ADHD symptoms. Lack of Perseverance moderated
just one effect; among women high in Lack of Perseverance (+1 SD above sample
average), higher average E2 was associated with lower hyperactive/impulsive symptoms
(γ = -.22 SE = .07, t(30) = -3.11, p = .004); the effect of average E2 was not significant
among women with low Lack of Perseverance (-1 SD below sample average).
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Phase analyses revealed a significant decrease in inattentive symptoms during the
premenstrual phase and a peak in symptoms during the post-ovulatory phase for those
high in Lack of Premeditation (see Figure 3.13).
Effect Size of Trait Moderators. Results of follow-up probing analyses reveal
that women with high sensation seeking, positive urgency, or negative urgency, when P4
is +1 person-SD above the person average, experience a change of roughly .10-.20 (one
tenth to one twenthieth) of an ADHD symptom with a 1 person-SD change in E2.
Effects of E2 and P4 on Alcohol Use
	
  
The second set of models focused on hormone variables as predictors of alcohol
use in the subsample of 22 women. For the multilevel model on this subsample, hormone
predictors and covariates were the same as above, but also included the covariate of legal
drinking status and the dichotomous predictor of weekend status (where Thursday
through Sunday = 1) Results of this model are presented in Table 3.7 (alcohol use), and
are summarized in the paragraphs that follow.
There were no significant between-person correlations of an individual’s
proportion of drinking days and their average levels of E2 or P4 (all p’s < .45 in full
sample; all p’s < .36 in drinking subsample). However, within-person results of models
predicting both daily drinking and daily binge drinking from person-standardized E2 and
P4 levels (one day prior to drinking outcome), and interactions of E2 and P4 with
weekend status are presented in Table 3.7. Significant interactions are depicted in Figure
3.14 and are further characterized using simple slope analyses at the bottom of Table 3.7.
There were significant three-way interactions between weekend status, E2, and P4
predicting both drinking and binge drinking. Hormones were predictive of drinking
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outcomes only on weekend days. Simple slope analyses, presented at the bottom of Table
3.7, indicated that higher-than-average E2 on weekend days predicted a greater likelihood
of drinking and binge drinking; these effects of E2 were strongest when P4 was lower
than usual, and were attenuated but still significant when P4 was higher than usual. A one
person-SD elevation above the person average of E2 was associated with a 26% increase
in the probability of drinking, and was associated with a 125% increase in the probability
of binge drinking when P4 was 1 person-SD below the person average. A similar
elevation of E2 was associated with a 19% increase in the probability of drinking and a
27% increase in the probability of binge drinking when P4 was 1 person-SD above the
person average. Thus, elevated P4 attenuated the effects of E2 elevations on increased
drinking on weekend days. Extrapolating the size of the effects reported in Table 3.2,
indicates that ovulation is associated with a 657% increase in odds of binge drinking on
the weekend (Odds Ratio = 7.57 for a 2.5 person-SD elevation in E2 above one’s person
average, at 1-SD below the P4 person average). Phase analyses were in line with these
results, showing a peak in drinking during the pre-ovulatory phase, when E2 is increasing
dramatically (see Figure 3.15).

	
  

26	
  

Table 3.1
Main Effects of Between- and Within-Person Ovarian Hormones on Daily Outcomes

Parameter

ADHD Sx
(0-18)

Intercept
BMI
Average E2
Average P4
Recent E2
Recent P4
Recent E2 X P4

.19 (.15)
.003 (.01)
-.08 (.04)
-.004 (.04)
-.04 (.02)
.02 (.03)
-.05* (.02)

Outcome
(Range of Scale)
Hyper/Imp
Sx
(0-9)
.09 (.10)
.002 (.004)
-.06* (.03)
.02 (.03)
-.03* (.01)
.03* (.02)
-.03* (.01)

Inattentive Sx
(0-9)
.11 (.10)
.003 (.004)
-.05 (.03)
-.02 (.03)
-.01 (.02)
-.001 (.02)
-.04* (.02)

Note. **p < .01, *p < .05. Recent E2 and P4 are person-standardized values from two
days prior to the outcome, calculated as today’s hormone value minus the woman’s
average value for that hormone across the entire cycle, divided by the woman’s standard
deviation for that hormone across the entire cycle. BMI, Average E2, and Average P4 are
sample-standardized.
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Table 3.2
Interactive Effects of Trait Negative Urgency and Ovarian Hormone Predictors on Daily
ADHD Symptoms
Outcome
(Scale)
Parameter

Total ADHD SX

Estimate
Intercept
0.22**
BMI
0.00
Average E2
-0.11
Average P4
-0.02
Recent E2
-0.03
Recent P4
0.03
Recent E2 X Recent P4
-0.06**
Trait Negative Urgency (NU) 0.17**
NU X Trait E2
-0.15*
NU X Trait P4
-0.09
NU X Recent E2
-0.02
NU X Recent P4
0.05
NU X Recent E2 X Recent P4 -0.08**

SE
0.05
0.05
0.06
0.06
0.02
0.02
0.02
0.06
0.06
0.08
0.02
0.03
0.02

Hyperactive Sx
Estimate
0.10**
0.00
-0.06
0.01
-0.03
0.04**
-0.04**
0.08*
-0.09*
-0.02
-0.03
0.05**
-0.04**

SE
0.03
0.02
0.03
0.03
0.01
0.01
0.01
0.03
0.03
0.04
0.02
0.02
0.01

Inattentive Sx
Estimate
0.15**
0.00
-0.08
-0.03
-0.02
0.01
-0.04**
0.13*
-0.10*
-0.09
-0.02
0.02
-0.06**

SE
0.04
0.04
0.05
0.05
0.02
0.02
0.02
0.05
0.05
0.06
0.02
0.02
0.02

Note. **p < .01, *p < .05. Recent E2 and P4 are person-standardized values from two
days prior to the outcome, calculated as today’s hormone value minus the woman’s
average value for that hormone across the entire cycle, divided by the woman’s standard
deviation for that hormone across the entire cycle. BMI, Average E2, Average P4, and
Negative Urgency (NU) are sample-standardized.
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Table 3.3
Interactive Effects of Trait Positive Urgency and Ovarian Hormone Predictors on Daily
ADHD Symptoms
Outcome
(Scale)
Parameter
Intercept
BMI
Average E2
Average P4
Recent E2
Recent P4
Recent E2 X Recent P4
Trait Positive Urgency (PU)
PU X Average E2
PU X Average P4
PU X Recent E2
PU X Recent P4
PU X Recent E2 X P4

Total ADHD SX
Estimate
0.25**
-0.03
-0.18**
0.05
-0.02
0.02
-0.05**
0.24**
-0.23**
-0.02
0.00
0.03
-0.06**

SE
0.04
0.03
0.04
0.04
0.02
0.02
0.02
0.04
0.04
0.04
0.02
0.02
0.02

Hyperactive Sx
Estimate
0.13**
-0.01
-0.10**
0.06*
-0.02
0.03*
-0.03*
0.12**
-0.12**
0.03
-0.01
0.04*
-0.03*

SE
0.02
0.02
0.03
0.03
0.01
0.01
0.01
0.03
0.03
0.03
0.01
0.02
0.01

Inattentive Sx
Estimate
0.17**
-0.02
-0.13**
0.01
0.00
-0.01
-0.04*
0.19**
-0.17**
-0.04
0.01
0.01
-0.06**

SE
0.03
0.03
0.03
0.03
0.02
0.02
0.02
0.03
0.03
0.03
0.02
0.02
0.02

Note. **p < .01, *p < .05. Recent E2 and P4 are person-standardized values from two
days prior to the outcome, calculated as today’s hormone value minus the woman’s
average value for that hormone across the entire cycle, divided by the woman’s standard
deviation for that hormone across the entire cycle. BMI, Average E2, Average P4, and
Positive Urgency (PU) are sample-standardized.
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Table 3.4
Interactive Effects of Trait Sensation Seeking and Ovarian Hormone Predictors on Daily
ADHD Symptoms
Outcome
(Scale)
Parameter
Intercept
BMI
Average E2
Average P4
Recent E2
Recent P4
Recent E2 X Recent P4
Trait Sensation Seeking (SS)
SS X Average E2
SS X Average P4
SS X Recent E2
SS X Recent P4
SS X Recent E2 X P4

Total ADHD SX
Estimate
0.21**
0.09
-0.11
0.07
-0.01
0.01
-0.05*
0.17**
0.01
-0.14
-0.01
0.03
-0.05*

SE
0.05
0.06
0.06
0.06
0.02
0.02
0.02
0.06
0.09
0.12
0.02
0.02
0.02

Hyperactive Sx
Estimate
0.11**
0.05
-0.07*
0.07
-0.02
0.03
-0.03*
0.10**
-0.02
-0.02
-0.01
0.03*
-0.03*

SE
0.03
0.03
0.03
0.03
0.01
0.01
0.01
0.03
0.05
0.07
0.01
0.02
0.01

Inattentive Sx
Estimate
0.14**
0.07
-0.08
0.03
0.00
-0.01
-0.04*
0.13**
0.01
-0.12
-0.01
0.02
-0.05**

SE
0.04
0.05
0.04
0.05
0.02
0.02
0.02
0.05
0.07
0.09
0.02
0.02
0.02

Note. **p < .01, *p < .05. Recent E2 and P4 are person-standardized values from two
days prior to the outcome, calculated as today’s hormone value minus the woman’s
average value for that hormone across the entire cycle, divided by the woman’s standard
deviation for that hormone across the entire cycle. BMI, Average E2, Average P4, and
Sensation Seeking (SS) are sample-standardized.
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Table 3.5
Interactive Effects of Trait Lack of Premeditation and Ovarian Hormone Predictors on
Daily ADHD Symptoms
Outcome
(Scale)
Parameter
Intercept
BMI
Average E2
Average P4
Recent E2
Recent P4
Recent E2 X Recent P4
Trait Lack of Premed (LPM)
LPM X Average E2
LPM X Average P4
LPM X Recent E2
LPM X Recent P4
LPM X Recent E2 X P4

Total ADHD SX
Estimate
0.21**
0.00
-0.12
0.00
-0.01
0.02
-0.05**
0.06
-0.11
-0.06
0.00
0.03
-0.03

SE
0.06
0.06
0.07
0.08
0.02
0.02
0.02
0.08
0.07
0.08
0.03
0.03
0.02

Hyperactive Sx
Estimate
0.12**
0.01
-0.09*
0.05
-0.02
0.03*
-0.03*
0.03
-0.06
0.01
-0.01
0.02
-0.01

SE
0.04
0.03
0.04
0.05
0.01
0.02
0.01
0.04
0.04
0.04
0.02
0.02
0.02

Inattentive Sx
Estimate
0.14**
-0.01
-0.08
-0.04
0.00
0.00
-0.04**
0.05
-0.08
-0.08
0.00
0.03
-0.03

SE
0.05
0.04
0.05
0.06
0.02
0.02
0.02
0.06
0.05
0.06
0.02
0.02
0.02

Note. **p < .01, *p < .05. Recent E2 and P4 are person-standardized values from two
days prior to the outcome, calculated as today’s hormone value minus the woman’s
average value for that hormone across the entire cycle, divided by the woman’s standard
deviation for that hormone across the entire cycle. BMI, Average E2, Average P4, and
trait Lack of Premeditation (LPM) are sample-standardized.
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Table 3.6
Interactive Effects of Trait Lack of Perseverance and Ovarian Hormone Predictors on
Daily ADHD Symptoms
Outcome
(Scale)
Parameter
Intercept
BMI
Average E2
Average P4
Recent E2
Recent P4
Recent E2 X Recent P4
Trait Lack of Persev (LPS)
LPS X Average E2
LPS X Average P4
LPS X Recent E2
LPS X Recent P4
LPS X Recent E2 X P4

Total ADHD SX
Estimate
0.22**
-0.01
-0.08
-0.01
-0.03
0.01
-0.04*
0.12
-0.17
0.06
-0.01
0.00
-0.01

SE
0.06
0.06
0.06
0.07
0.02
0.02
0.02
0.07
0.09
0.09
0.03
0.03
0.03

Hyperactive Sx
Estimate
0.10**
-0.01
-0.06
0.02
-0.02
0.03
-0.02**
0.05
-0.13**
0.08
-0.02
0.00
0.01

SE
0.03
0.03
0.03
0.03
0.01
0.01
0.01
0.04
0.04
0.05
0.02
0.02
0.02

Inattentive Sx
Estimate
0.16**
0.00
-0.05
-0.03
-0.01
0.00
-0.03
0.10
-0.10
0.00
0.02
-0.02
-0.01

SE
0.05
0.05
0.05
0.06
0.02
0.02
0.02
0.06
0.07
0.08
0.02
0.02
0.02

Note. **p < .01, *p < .05. Recent E2 and P4 are person-standardized values from two
days prior to the outcome, calculated as today’s hormone value minus the woman’s
average value for that hormone across the entire cycle, divided by the woman’s standard
deviation for that hormone across the entire cycle. BMI, Average E2, Average P4, and
Trait Lack of Perseverance (LPS) are sample-standardized.

	
  

32	
  

Table 3.7
Models Predicting Daily Alcohol Use from Weekend Status and Recent Ovarian Steroid
Levels
Outcome
Daily Alcohol Use

Parameter
Intercept
BMI
Legal Drinking Status
Weekend Status
Recent E2
Recent P4
Recent E2 × Recent P4
Wknd × Recent E2
Wknd × Recent P4
Wknd × Recent E2 × Recent P4

Estimate
-2.33**
0.11
0.14*
0.93*
0.28*
-0.08
-0.08
0.00
0.00
0.04**

SE
0.40
0.22
0.06
0.37
0.12
0.18
0.12
0.01
0.28
0.01

Daily Binge Drinking
(>=4 Drinks)
Estimate
-4.72**
-.20
0.02
2.20*
1.00**
0.37*
-0.05
-0.33
-0.99**
-0.12*

SE
0.85
.65
.69
0.71
0.33
0.18
0.22
0.59
0.38
0.06

Simple Effects of Within-Person E2 Levels on the Weekend
At Low P4
Odds Ratio (95% CI)

0.23*
0.11
1.25 (1.02 to 1.56)

0.81*
0.36
2.24 (1.11 to 4.55)

At High P4
Odds Ratio (95% CI)

0.17*
0.083
1.18 (1.01 to 1.39)

0.24*
0.11
1.27 (1.02 to 1.57)

Note. *p < .05, **p < .01, ***p < .001. All hormones are standardized within person and
calculated as today’s value minus one’s person average, divided by one’s person standard
deviation. E2 = Estradiol, P4 = Progesterone. Low P4 = 1 standard deviation below the
person average; High P4 = 1 standard deviation above the person average. Significant
fixed effects are shown in bold.
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Interactive Effects of Recent E2 and P4
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Figure 3.1. Interactive Effects of Person-Standardized Recent E2 and P4 on ADHD
Symptoms in Women Across One Menstrual Cycle.
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*	
  
*	
  
*	
  

Figure 3.2. Phase analyses of Hyperactive-Impulsive Symptoms (TOP) and Inattentive
Symptoms (BOTTOM). *Indicates a significant difference (p < .05) between phases.
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Effect of Mean E2
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Figure 3.3. Interactive Effects of Trait Negative Urgency and Average E2 on Average
Daily ADHD Symptoms in Women Across One Menstrual Cycle.
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Interactive Effects of Recent E2 and P4 in
Women with
High Negative Urgency
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Figure 3.4. Interactive Effects of Trait Negative Urgency with Recent E2 and P4 (PersonStandardized) on Daily ADHD Symptoms in Women Across One Menstrual Cycle.
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Figure 3.5. Interactive Effects of Trait Positive Urgency and Average E2 on Average
Daily ADHD Symptoms in Women Across One Menstrual Cycle.
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Figure 3.6. Interactive Effects of Trait Positive Urgency and Average P4 on Average
Daily Hyperactive Symptoms in Women Across One Menstrual Cycle.
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Figure 3.7. Interactive Effects of Trait Positive Urgency with Recent E2 and P4 (PersonStandardized) on Daily ADHD Symptoms in Women Across One Menstrual Cycle.
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*	
  

Figure 3.8. Phase analyses of Inattentive Symptoms for those high and low in trait
Negative Urgency (there was no significant variability for Hyperactive-Impulsive
Symptoms). *Indicates a significant difference (p < .05) between phases for the full
sample.
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Hyperactive/Impulsive Symptoms Across the Menstrual Cycle
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Figure 3.9. Phase analyses of Hyperactive-Impulsive Symptoms (TOP) and Inattentive
Symptoms (BOTTOM) for those high and low in trait Positive Urgency. *Indicates a
significant difference (p < .05) between phases for the full sample.
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Figure 3.10. Interactive Effects of Trait Sensation Seeking with Recent E2 and P4
(Person-Standardized) on Daily ADHD Symptoms in Women Across One Menstrual
Cycle.
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*	
  
*	
  

Figure 3.11. Phase analyses of Hyperactive-Impulsive (TOP) and Inattentive (BOTTOM)
Symptoms for those high and low in trait Sensation Seeking. *Indicates a significant
difference (p < .05) between phases for the full sample.
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Effect of Mean E2
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Figure 3.12. Interactive Effects of Trait Lack of Perseverance and Average E2 on
Average Daily Hyperactive Symptoms in Women Across One Menstrual Cycle.
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Figure 3.13. Phase analyses of Inattentive Symptoms for those high and low in trait Lack
of Premeditation (there was no significant variability in Hyperactive-Impulsive
symptoms). *Indicates a significant difference (p < .05) between phases for the full
sample.
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Interactive Within-Person Effects of E2 and P4
on Weekend Drinking
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Figure 3.14. Interactive Within-Person Effects of Recent E2 Levels and Recent P4 Levels
on Drinking (TOP) and Binge Drinking (BOTTOM) on Weekend Days
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Figure 3.15. Phase analyses for probability of drinking (TOP) and binge drinking
(BOTTOM) across the cycle. *Indicates a significant difference (p < .05) between
phases.
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CHAPTER FOUR: DISCUSSION
	
  
Although research suggests that women with ADHD may exhibit greater
impairment at puberty, no prior study has directly examined circulating hormone levels in
relation to ADHD symptoms and other risk-taking behaviors in young adulthood, the
goals of the present study. In line with prior work on hormones and EF and in line with
study hypotheses, lower average between-person levels of E2, and periods of lower-thanaverage E2 across the cycle, increased risk for ADHD symptoms. However, results
demonstrated the importance of interactions between E2 and P4. Within-person effects of
low E2 were only significant when recent P4 was also higher-than-average (i.e. in the
luteal phase). Specifically, women with lower-than-average levels of E2 reported higher
hyperactive-impulsive symptoms during periods of higher concurrent levels of P4.
Further, somewhat in line with study hypotheses, only women who were high on the
traits of negative urgency, positive urgency, or sensation seeking (but not high in lack of
perseverance or premeditation) exhibited an association between lower-than-average E2
levels and high ADHD symptoms. In contrast to study hypotheses, high within-person E2
was associated with increased drinking particularly in the context of low P4. Overall,
study results suggest multiple pathways to ADHD symptoms contingent on the
interactive effects for hormones, at least for women at-risk based on affective personality
factors, and these effects differ from what is seen in relation to risk-taking behavior such
as binge drinking.
Hormonal Effects on ADHD Symptoms
	
  
Results demonstrated that lower-than-average E2 in the context of higher-thanaverage P4 is associated with increased symptoms, in line with case studies suggesting
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symptoms of ADHD worsen the week before menstruation, when E2 falls from its midluteal peak and P4 is still higher-than-average (Quinn, 2005). In fact, our phase analyses
suggested an early luteal, or post-ovulatory, increase in ADHD symptoms (seemingly
driven by post-ovulatory and peri-menstrual reductions in E2). These findings are in line
with research demonstrating that high E2 facilitates cognitive functioning in women with
decreases in E2 being risky for cognitive functioning, EF, and attention (Jacobs et al.,
1998; Schmidt et al., 1996; Sherwin, 1997). These effects may be mediated through E2
effects on the dopamine system, since lower synaptic dopamine and dopamine receptors
are correlated with lower E2 levels (Archer, 1999; Gibbs, 2010). ADHD is also
associated with lower extracellular dopamine and medications used to treat ADHD
increase dopamine levels (Volkow et. al., 2001), but high E2 appears to enhance
dopamine; thus, it appears to be protective against ADHD symptoms. In any case, low or
declining levels of E2 seem to be risky for ADHD symptoms.
However, these effects of hormones on ADHD symptoms may only be important
for some women. Somewhat in line with study hypotheses, only women who were high
on the traits of negative urgency, positive urgency or sensation seeking showed a
negative association between lower-than-average E2 levels and high ADHD symptoms,
and only women high on the trait of lack of perseverance showed a negative association
between average levels of E2 and high hyperactive-impulsive symptoms. In contrast to
study hypotheses, the other facet of impulsivity, lack of premeditation, did not moderate
any hormone effects on ADHD symptoms. These urgency-related effects during the
luteal phase of the menstrual cycle replicate findings from a study of a personality
phenotype characterized by negative urgency (Borderline Personality Disorder). That
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study showed an identical pattern of interactive within-person effects of E2 and P4 on
impulsivity and related psychopathology among women high in trait borderline features
(Eisenlohr-Moul et al., 2015), which are characterized by a behavioral phenotype highly
similar to negative urgency (Settles et al., 2012).
Hormonal Effects on Risk-Taking
	
  
The results of hormonal effects on drinking were in contrast to study hypotheses
and results of hormonal effects on ADHD symptoms. The effects of E2 and P4 on alcohol
use (in the subsample of women who drank alcohol) suggested that higher-than-average
recent levels of E2, in the co-occurring contexts of (1) lower-than-average P4 (i.e. the
follicular phase) and (2) during the weekend, were associated with increased risk of
drinking and binge drinking. Though this effect of E2 was significant at all levels of P4,
the effect was stronger when P4 was low and weaker when P4 was high, likely reflecting
the antagonistic influence of P4 on E2 (Singh, Su, & Ng, 2013) and further highlighting
the importance of the interactions of P4 and E2 (Klump et al., 2008; 2013; EisenlohrMoul et al., 2015).
The effects of E2 and P4 on drinking may also be mediated through dopamine and
GABA. For example, animal studies suggest that high E2 decreases GABA
neurotransmission, which increases dopamine release in the striatum and nucleus
accumbens (Becker & Hu, 2008; Lynch, Roth, & Carroll, 2002). Additionally, high E2
down-regulates dopamine receptor binding (Becker & Hu, 2008). Abnormalities in
dopaminergic neurotransmission and elevated E2 can increase reward sensitivity, which
is a key mechanism of substance craving, use, and other risk-taking behaviors (Dreher et
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al., 2007; Hyman, Malenka, & Nestler, 2006; Koob & Le Moal, 2001; Lofgren et al.,
2009; Robinson & Berridge, 1993; Volkow et al., 2010).
Results are consistent with increases in female risk-taking behaviors around
ovulation, in line with evolutionary developmental theory suggesting that females may be
more likely to engage in risk-taking behaviors such as alcohol use as they approach
ovulation, potentiated by rising E2, which might operate to facilitate conception
(Gangestad, Thornhill, & Garver-Apgar, 2002; Geary, 2010; Larson et al., 2013). This
might also provide a partial explanation for increases in alcohol use and other risk-taking
behaviors around puberty (Spear, 2010), again potentiated by rapidly rising levels of sex
steroids, and at a time when fertility is increasing. Furthermore, such results suggest a
large impact of environmental influences, such as opportunity for drinking and
availability of alcohol on weekends on college campuses.
Clinical Implications
	
  
The present study challenges current research practices by suggesting that ADHD
symptom presentation in post-pubertal females may fluctuate across the cycle. Perhaps, if
the presentation of ADHD in post-pubertal women is not static, then it might not
constitute a true trait, as currently conceptualized in DSM-5 (APA, 2013). Rather, ADHD
in women might be better conceptualized as a series of states in which some symptoms
may worsen due to biological changes. Further, it is possible that women may also
fluctuate through their life -and even within a single month- to the degree that they would
not always meet DSM-5 criteria for ADHD. Prior work has suggested that women go
undiagnosed due to the higher incidence of inattentive versus hyperactive-impulsive
symptoms among women (Gaub & Carlson, 1997; Gershon & Gershon, 2002). However,
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the present study suggests another alternative. Perhaps some women do not reach
diagnostic threshold or impairment until hormones rise and begin to cycle at puberty.
These findings suggest a number of potential implications for the diagnosis and
treatment of women with ADHD. For example, results support that clinicians may need
to know a woman’s cycle phase and hormonal status, including medications that affect
hormone levels like birth control, when assessing ADHD in young women (Quinn &
Nadeau, 2002). Finally, trait levels of impulsivity may be important to consider in
assessments, and inclusion of assessment of trait impulsivity may help to identify those
women who are more at risk for hormonal influences on ADHD symptoms.
Limitations and Future Directions
	
  
This study has a number of notable strengths as it was the first, to my knowledge,
to directly and empirically examine associations between E2 and ADHD symptoms,
associated risk-taking behaviors, and a marker of the disorder, namely impulsivity.
However, it is not without limitations. Importantly, the present study utilized a
community (vs. clinical) sample, which may limit the generalizability of these findings,
despite the fact that research suggests ADHD is best characterized by a continuous
dimension (Barkley, 2006; Haslam et al., 2006; Larsson, Anckarsater, Råstam, Chang,
and Lichtenstein, 2012; Marcus & Barry, 2011). The distribution of ADHD symptoms in
the current sample was positively skewed, and risky behaviors were rare. Future studies
should include larger samples and include more women meeting diagnostic criteria for
ADHD and samples with higher rates of drinking, substance use and risky sexual
behaviors. However, obtaining a sample of women willing and able to complete 35 days
of data collection successfully was challenging; obtaining a sample of women with
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ADHD who could also accomplish this task, requiring a high level of conscientiousness
and organization, would be even more of a challenge. The present study also relied on
women’s self-report. Future studies could utilize other report measures of symptoms
(which we had on only a very small subsample of the women) and/or other measures of
impulsivity and/or impulse control, such as neuropsychological testing.
Recent experimental work suggests that it may be acute change in E2 or P4
(rather than higher or lower than average levels) that can have a dysregulating effect on
brain function and behavior in susceptible women (reviewed in Schiller et al., 2016 and
Gordon et al., 2015). Therefore, it is possible that the effects of lower-than-average E2 in
the present study are attributable in part to the acute, day-to-day effects of withdrawal
from E2 in the luteal phases of vulnerable women. Although post-hoc analyses
examining the effects of two-day changes in hormones did not reveal a consistent pattern
of effects, it is possible that the effects of hormone change operate on a shorter lag (e.g.,
24-hour change) than was possible here with every-other-day hormone sampling (i.e., 48hour change). Future work with daily samples of E2 and P4 could assess the degree of
impact of a 24-hour change in hormones, in addition to relative recent hormone levels
when assessing their relationship with ADHD symptoms.
There are numerous other important directions for future work. Due to E2’s
effects on cognitive functioning and symptoms, results of neuropsychological testing
could be affected, and this should be examined. Further, the effect of E2 and P4 on
psychostimulant medication response and efficacy is another important area for future
research with large clinical implications. Additionally, the effects of birth control on
ADHD symptoms and psychostimulants are important areas for future research. For
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example, studies could compare the effects of 21/7 birth control to 24/4 or continuous
birth control methods, as the latter may decrease fluctuations in P4 and E2 (Sullivan,
1999) and could be beneficial for women with ADHD. Future studies should also
examine potentially developmental effects of hormones across different important
developmental periods (e.g., puberty, menopause) and pregnancy. The present study
stressed the importance of consideration of interactions between E2 and P4 in line with
some previous studies (Klump et al., 2008; 2013; Eisenlohr-Moul et al., 2015). Further
studies should also examine the interaction of other hormones that may affect
psychopathology and cognition, such as testosterone and dehydroepiandrosterone.
Incorporating associated genetic factors (e.g. DRD2, COMT etc.) is another promising
avenue for future research.
State impulsivity was not assessed in the present study after data inspection
revealed data as suspect. The response scale of the state measure of impulsivity, a
shortened version of UPPS, was coded in such a way that the likert scale was in reverse
of other measures. Given this finding, and the negative correlation of the state measure to
the trait UPPS, the data seemed suspect and could not be utilized for analyses. Future
studies should examine whether state impulsivity mediates the association of hormones
and ADHD, perhaps due to their similar brain pathways involving the amygdala,
orbitofrontal cortex, and ventromedial prefrontal cortex (Cyders & Smith, 2008).
Conclusion
	
  
The present study suggests a great deal of complexity in the presentation of
ADHD in young adult women. Low levels and decreases in E2 appear to worsen ADHD
symptoms, challenging the conceptualization of ADHD as a trait, at least in young adult
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women high in trait impulsivity. These relationships are significant only in the context of
high P4, and only among women who are high in certain types of trait impulsivity,
further suggesting ADHD is a heterogeneous disorder characterized by equifinality.
These results may have implications for assessment and treatment approaches for young
women with ADHD.
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